argenx SE (ARGX)

業務介紹

argenx SE是一家生物科技公司，專注於在美國、荷蘭、比利時、日本、瑞士、德國和法國開發各種治療自體免疫性疾病的療法。其主要產品候選藥物是efgartigimod，用於治療重症肌無力、免疫性血小板減少性紫癜、天疱瘡和慢性炎性脫髓鞘性多神經病，在III期臨床試驗中；在II/III期臨床試驗中，用於治療水疱性類天疱瘡和特發性炎性肌病；以及在臨床前研究中的ENHANZE SC。該公司還正在開發免疫學創新計劃，包括用於治療血液腫瘤和高風險骨髓增生異常症的cusatuzumab；針對肌肉特異性酪氨酸激酶階段的抗體ARGX-119；用於嚴重自體免疫性疾病的ARGX-117；用於氣道炎症的ARGX-118；以及用於治療自體免疫性疾病的ARGX-120。此外，其合作產品候選藥物包括用於治療癌症的ARGX-115；用於治療白細胞介素-22受體的ARGX-112；以及針對MET受體的抗體ARGX-114。該公司與AbbVie S.À.R.L.、Zai Lab Limited和LEO Pharma A/S建立了戰略合作夥伴關係；並與Genor Biopharma Co. Ltd、Université Catholique de Louvain、Sopartec S.A.、NYU Langone Health、Leiden University Medical Center、AgomAb Therapeutics NV、Broteio Pharma B.V.、University of Texas、BioWa, Inc.、Cilag GmbH International、Staten Biotechnology B.V.和Shire International GmbH簽訂了合作和許可協議。argenx SE成立於2008年，總部位於荷蘭的布雷達。

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

公司網址

https://www.argenx.com